2. Academic Validation
  3. The Mycobacterium tuberculosis MmpL3 inhibitor MSU-43085 is active in a mouse model of infection

The Mycobacterium tuberculosis MmpL3 inhibitor MSU-43085 is active in a mouse model of infection

  • Microbiol Spectr. 2024 Jan 11;12(1):e0367723. doi: 10.1128/spectrum.03677-23.
John T Williams 1,  Matthew Giletto 2,  Elizabeth R Haiderer 1,  Bilal Aleiwi 2,  Teresa Krieger-Burke 2,  Edmund Ellsworth 2,  Robert B Abramovitch 1
Affiliations

Affiliations

  • 1 Department of Microbiology and Molecular Genetics, Michigan State University , East Lansing, Michigan, USA.
  • 2 Department of Pharmacology and Toxicology, Michigan State University , East Lansing, Michigan, USA.
PMID: 38078724 DOI: 10.1128/spectrum.03677-23
Abstract

MmpL3 is a protein that is required for the survival of bacteria that cause tuberculosis (TB) and nontuberculous mycobacterial (NTM) infections. This report describes the discovery and characterization of a new small molecule, MSU-43085, that targets MmpL3 and is a potent inhibitor of Mycobacterium tuberculosis (Mtb) and M. abscessus survival. MSU-43085 is shown to be orally bioavailable and efficacious in an acute model of Mtb Infection. However, the analog is inactive against Mtb in chronically infected mice. Pharmacokinetic and metabolite identification studies identified in vivo metabolism of MSU-43085, leading to a short half-life in treated mice. These proof-of-concept studies will guide further development of the MSU-43085 series for the treatment of TB or NTM infections.

Keywords

MmpL3; Mycobacterium tuberculosis; drug development; nontuberculous mycobacteria.

Figures
Products